$ALDX
Aldeyra Therapeutics, Inc.

2018 Q4 Form 10-Q Financial Statement

#000119312518326837 Filed on November 14, 2018

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2017 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.550M $3.070M $1.480M
YoY Change 70.0% 107.43% 5.71%
% of Gross Profit
Research & Development $8.550M $7.881M $3.539M
YoY Change 54.05% 122.66% 4.72%
% of Gross Profit
Depreciation & Amortization $20.00K $20.00K $10.00K
YoY Change 100.0% 100.0% 0.0%
% of Gross Profit
Operating Expenses $11.09M $7.881M $3.539M
YoY Change 57.3% 122.66% 4.72%
Operating Profit -$10.95M -$5.015M
YoY Change 118.27% 5.0%
Interest Expense $460.0K $28.85K $27.58K
YoY Change 411.11% 4.6% 3.47%
% of Operating Profit
Other Income/Expense, Net $134.2K $29.07K
YoY Change 361.49% 2454.75%
Pretax Income -$10.63M -$10.81M -$4.990M
YoY Change 52.95% 116.68% 4.39%
Income Tax
% Of Pretax Income
Net Earnings -$10.63M -$10.81M -$4.986M
YoY Change 52.95% 116.85% 4.42%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$405.1K -$515.5K -$320.3K
COMMON SHARES
Basic Shares Outstanding 26.24M shares 20.97M shares 15.15M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q4 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $93.60M $35.10M $47.90M
YoY Change 118.18% -26.72% 65.74%
Cash & Equivalents $47.36M $18.01M $33.10M
Short-Term Investments $46.24M $17.10M $14.80M
Other Short-Term Assets $1.200M $1.700M $1.100M
YoY Change 20.0% 54.55% 266.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $94.77M $36.85M $49.05M
YoY Change 115.55% -24.89% 68.42%
LONG-TERM ASSETS
Property, Plant & Equipment $235.2K $243.5K $38.02K
YoY Change 443.72% 540.46% -42.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $0.00 $100.0K
YoY Change -50.0% -100.0%
Total Long-Term Assets $321.9K $286.5K $176.7K
YoY Change 53.86% 62.15% 168.96%
TOTAL ASSETS
Total Short-Term Assets $94.77M $36.85M $49.05M
Total Long-Term Assets $321.9K $286.5K $176.7K
Total Assets $95.09M $37.13M $49.23M
YoY Change 115.26% -24.57% 68.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.052M $3.442M $485.3K
YoY Change 204.87% 609.38% -33.85%
Accrued Expenses $5.421M $3.746M $1.507M
YoY Change 142.41% 148.5% 2.09%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $465.3K $426.5K
YoY Change -100.0% 9.09% 0.0%
Total Short-Term Liabilities $8.473M $7.654M $2.419M
YoY Change 152.65% 216.37% -8.25%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $882.8K $905.3K
YoY Change -100.0% -2.48% 2.49%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $882.8K $905.3K
YoY Change -100.0% -2.48% 2.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.473M $7.654M $2.419M
Total Long-Term Liabilities $0.00 $882.8K $905.3K
Total Liabilities $8.473M $8.537M $3.324M
YoY Change 85.25% 156.78% -5.55%
SHAREHOLDERS EQUITY
Retained Earnings -$138.5M -$127.9M -$92.69M
YoY Change 39.03% 37.99% 27.58%
Common Stock $225.2M $156.5M $138.6M
YoY Change 61.68% 12.92% 40.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $86.62M $28.60M $45.90M
YoY Change
Total Liabilities & Shareholders Equity $95.09M $37.13M $49.23M
YoY Change 115.26% -24.57% 68.64%

Cashflow Statement

Concept 2018 Q4 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income -$10.63M -$10.81M -$4.986M
YoY Change 52.95% 116.85% 4.42%
Depreciation, Depletion And Amortization $20.00K $20.00K $10.00K
YoY Change 100.0% 100.0% 0.0%
Cash From Operating Activities -$7.970M -$7.690M -$4.700M
YoY Change 58.76% 63.62% 33.9%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$50.00K $0.00
YoY Change 0.0%
Acquisitions
YoY Change
Other Investing Activities -$28.96M $30.00K -$3.630M
YoY Change 257.97% -100.83% -736.84%
Cash From Investing Activities -$28.98M -$20.00K -$3.630M
YoY Change 257.34% -99.45% -748.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $26.90M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 66.29M 1.120M 26.83M
YoY Change 132480.0% -95.83% -26930.0%
NET CHANGE
Cash From Operating Activities -7.970M -7.690M -4.700M
Cash From Investing Activities -28.98M -20.00K -3.630M
Cash From Financing Activities 66.29M 1.120M 26.83M
Net Change In Cash 29.34M -6.590M 18.50M
YoY Change -324.31% -135.62% -706.56%
FREE CASH FLOW
Cash From Operating Activities -$7.970M -$7.690M -$4.700M
Capital Expenditures -$10.00K -$50.00K $0.00
Free Cash Flow -$7.960M -$7.640M -$4.700M
YoY Change 58.88% 62.55% 33.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3442370
CY2018Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5196
CY2018Q3 us-gaap Assets
Assets
37131593
CY2018Q3 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
17133925
CY2018Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
28139121
CY2018Q3 us-gaap Cash
Cash
5905553
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18008652
CY2018Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26244434 shares
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33103849
CY2018Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3746037
CY2018Q3 us-gaap Assets Current
AssetsCurrent
36845110
CY2018Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
29237024
CY2018Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
156481258
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20989302 shares
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20989302 shares
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
20989
CY2018Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1176329
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7653685
CY2018Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2018Q3 us-gaap Liabilities
Liabilities
8536526
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
37131593
CY2018Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
465278
CY2018Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
882841
CY2018Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
1103099
CY2018Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
243483
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2018Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Liabilities
Liabilities
4573939
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44174958
CY2017Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
116319
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1220192
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1702533
CY2018Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q3 us-gaap Securities For Reverse Repurchase Agreements
SecuritiesForReverseRepurchaseAgreements
11000000
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-127901984
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
15195549
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1725007 shares
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.99
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3512163 shares
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.10
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
27056003
CY2018Q3 us-gaap Share Price
SharePrice
13.80
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
28595067
CY2018Q3 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
17139121
CY2018Q3 aldx Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
428234
CY2018Q3 aldx Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
43000
CY2018Q3 aldx Fair Value Of Warrant Issued
FairValueOfWarrantIssued
266000
CY2018Q3 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
2141474
CY2015Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1100000 shares
CY2015Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
7.00
CY2015Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.50
CY2015Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
211528 shares
CY2015Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
9.33
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12015061
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2236465
CY2017Q4 us-gaap Assets Current
AssetsCurrent
43965766
CY2017Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
41967314
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
139241635
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1000963
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-17831
CY2017Q4 us-gaap Assets
Assets
44174958
CY2017Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
22923462
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20023337
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19137639 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19137639 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
19138
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
788570
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3353747
CY2017Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
43262
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1018967
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-99641923
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2246857 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.87
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
39601019
CY2017Q4 aldx Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
120792
CY2017Q4 aldx Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
165930
CY2017Q4 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1327103
CY2015Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
7100000
CY2015Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
1100000 shares
CY2015Q1 invest Investment Warrants Exercise Price
InvestmentWarrantsExercisePrice
0.125
CY2015Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
1900000
CY2015Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
211528 shares
CY2015Q1 aldx Class Of Warrant Or Rights Expire Month Year
ClassOfWarrantOrRightsExpireMonthYear
2018-01
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2122668
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3778593 shares
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
15588
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-165562
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
21088788
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15387210
us-gaap Depreciation
Depreciation
29927
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.04
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4684574
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
209826
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
923045
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-438793
us-gaap Interest Expense
InterestExpense
80878
us-gaap Interest Paid Net
InterestPaidNet
64024
us-gaap Investment Income Interest
InvestmentIncomeInterest
136652
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
55774
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2087867
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
37381000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14204345
us-gaap Net Income Loss
NetIncomeLoss
-15386079
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1131
us-gaap Operating Income Loss
OperatingIncomeLoss
-15441853
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1131
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
20198275
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11592
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37474106
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
45555
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
18122000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10757279
us-gaap Share Based Compensation
ShareBasedCompensation
2122669
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14844914 shares
aldx Deferred Offering Costs Paid In Cash
DeferredOfferingCostsPaidInCash
138661
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3126919
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3784460 shares
dei Amendment Flag
AmendmentFlag
false
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
11608
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
82996
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2014685
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28247426
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Depreciation
Depreciation
48161
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Type
DocumentType
10-Q
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.40
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1509572
us-gaap Interest Expense
InterestExpense
83248
us-gaap Interest Paid Net
InterestPaidNet
81968
us-gaap Investment Income Interest
InvestmentIncomeInterest
427361
dei Entity Central Index Key
EntityCentralIndexKey
0001341235
dei Entity Registrant Name
EntityRegistrantName
ALDEYRA THERAPEUTICS, INC.
dei Entity Small Business
EntitySmallBusiness
true
dei Document Period End Date
DocumentPeriodEndDate
2018-09-30
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7330142
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2441407
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
683566
us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="4%" align="left"><b>1.</b></td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>NATURE OF BUSINESS</b></p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> Aldeyra Therapeutics, Inc. (the Company or Aldeyra), a Delaware corporation, is developing next-generation medicines to improve the lives of patients with immune-mediated diseases.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The Company&#x2019;s principal activities to date include research and development activities.</p> </div>
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
344113
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5636786
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14237485
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21888956
us-gaap Net Income Loss
NetIncomeLoss
-28260061
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
12635
us-gaap Operating Income Loss
OperatingIncomeLoss
-28604174
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
12635
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
21573832
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
248382
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14194871
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
85614
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
27459000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21274032
us-gaap Share Based Compensation
ShareBasedCompensation
3126919
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y11M8D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y9M25D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
1.00 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1265306 shares
dei Trading Symbol
TradingSymbol
ALDX
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.27
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"> <b><i>Use of estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with US&#xA0;GAAP requires management to make estimates and assumptions, including fair value estimates for investments that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#x2019;s financial statements relate to accruals, including research and development costs, accounting for income taxes and the related valuation allowance and accounting for stock based compensation and the related fair value. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</p> </div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20168633 shares
aldx Deferred Offering Costs Paid In Cash
DeferredOfferingCostsPaidInCash
43000
aldx Number Of Incentive Plans
NumberOfIncentivePlans
3 Incentive_Plan
aldx Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1.00 pure
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
659339
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3778593 shares
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4982561
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1475904
CY2017Q3 us-gaap Interest Expense
InterestExpense
27578
CY2017Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
56651
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
29073
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-4986199
CY2017Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
3638
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5015272
CY2017Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3638
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3539368
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15581426 shares
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1273720
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3784460 shares
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10815202
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.52
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3065912
CY2018Q3 us-gaap Interest Expense
InterestExpense
28846
CY2018Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
163015
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
134169
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-10812565
CY2018Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2637
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10946734
CY2018Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2637
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7880822
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20969913 shares

Files In Submission

Name View Source Status
0001193125-18-326837-index-headers.html Edgar Link pending
0001193125-18-326837-index.html Edgar Link pending
0001193125-18-326837.txt Edgar Link pending
0001193125-18-326837-xbrl.zip Edgar Link pending
aldx-20180930.xml Edgar Link completed
aldx-20180930.xsd Edgar Link pending
aldx-20180930_cal.xml Edgar Link unprocessable
aldx-20180930_def.xml Edgar Link unprocessable
aldx-20180930_lab.xml Edgar Link unprocessable
aldx-20180930_pre.xml Edgar Link unprocessable
d623698d10q.htm Edgar Link pending
d623698dex1030.htm Edgar Link pending
d623698dex1031.htm Edgar Link pending
d623698dex311.htm Edgar Link pending
d623698dex312.htm Edgar Link pending
d623698dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g623698g03m28.jpg Edgar Link pending
g623698g1112235129781.jpg Edgar Link pending
g623698img01.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending